(Updated - June 18, 2025 12:30 PM EDT) Caris Life Sciences (CAI) debuted on NYSE at $27 on Wednesday, after pricing its IPO at... Today’s IPO for Caris Life Sciences (CAI) is indicated to open ...

Caris Life Sciences Announces New Study Demonstrating the Power and Clinical Utility of its Caris Assure® Blood-Based Assay for Multi-Cancer Early Detection, Minimal Residual Disease and Therapy ...

Caris Life Sciences ® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions ...

Scientific Reports study validates the first multifunctional, AI-enabled blood-based assay to offer diagnostic, prognostic and predictive utility in a single assay. IRVING, Texas, July 8, 2025 ...

Caris or its distributor partners provide services in the U.S. and other international markets. The Scientific Report study is available on CarisLifeSciences.com. Forward Looking Statements: This ...

For deeper insights into Caris Life Sciences’ financial health and growth potential, including exclusive ProTips and detailed valuation analysis, visit InvestingPro.

IRVING, Texas - Caris Life Sciences (NASDAQ:CAI), a healthcare diagnostics company with a market capitalization of $7.37 billion and annual revenue of $452.5 million, announced Tuesday that a study ...

Review which funds and institutions currently hold Caris Life Sciences Inc (CAI:XNAS) stock for ownership information.

Nasus Pharma has filed for an initial public offering. The pharmaceutical company plans to offer 1 million units at $10 to $12 apiece for total proceeds of up to $12 million, according to a filing ...

The digital health market is welcoming new IPOs for the first time in years. Bankers and investors think these 9 startups ...